Yale Medicine posted the following article on July 15th.
Delta is the name for the B.1.617.2. variant, a SARS-CoV-2 mutation that originally surfaced in India. The first Delta case was identified in December 2020, and the strain spread rapidly, soon becoming the dominant strain of the virus in both India and then Great Britain. Toward the end of June, Delta had already made up more than 20% of cases in the U.S., according to Centers for Disease Control and Prevention (CDC) estimates. That number is rising swiftly, prompting predictions that the strain will soon become the dominant variant here.
Just when travel internationally was starting to open up, the Delta variant has paused some of those efforts. The Delta variant also appears to also affect individuals that have been vaccinated. The challenge for sponsors now is how to best launch training for a new trial in this uncertain environment.
Many investigators believe that the Pro-ficiency is a superior alternative to in-person investigators meetings. It is not surprising that they prefer the Pro-ficiency simulation approach over being trapped in on-line Zoom sessions or other eLearning platforms. The following results, however, are a higher bar. It appears that investigators are not longing to return to in-person training in a hotel ballroom.
With almost 90% neutral to positive, imagine providing a better training experience without the cost and uncertainty of clinicians traveling into an investigator meeting.
The ultimate measure of success is whether the training assisted the site staff in avoiding protocol deviations. Over 87% agreed or strongly agreed with that statement.
In summary, there are many advantages to the Pro-ficiency approach illustrated in this data:
- Investigators prefer the simulation training approach over all other methods
- Simulation training is an efficacious and efficient means of educating site staff
Let Pro-ficiency keep your study launch on track in these uncertain times with our simulation training platform!